Dhipatimendi rePasi Pose

Musi wa22 Ndira, 2025, "Nature Medicine" yakaburitsa zvakabuda muAkeso yakagadzira yega PD-1/CTLA-4 bispecific antibody cadonilimab pamwe chete neoxaliplatin necapecitabine kuti irapwe mushonga wekurapa chirwere chemudumbu chisina kubviswa kana kuti chakapararira munzvimbo iyoyo...Verenga zvakawanda»

Musi wa8 Ndira, 2025, National Medical Products Administration (NMPA) yeChina yakabvumidza PADCEVTM (enfortumab vedotin) pamwe chete neKEYTRUDA (pembrolizumab) kuvarwere vakuru vane kenza yemudumbu yakakwira kana kuti yakapararira (la/mUC). Kubvumidzwa kweNMPA kwe enfortumab vedotin mukamu...Verenga zvakawanda»

Musi wa17 Kukadzi, 2025, Innovent Biologics yakazivisa kuti protein yayo yekutanga yePD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, yakagamuchira Fast Track Designation yayo yechipiri (FTD) kubva kuUS Food and Drug Administration (FDA). Zita iri rinoshanda pakurapa kwemishonga isingarapwe, ...Verenga zvakawanda»

Musi wa16 Ndira, 2025, IMPACT yakazivisa kuti Senaparib Capsules (派舒宁®）yakagamuchira mvumo yekutengesa muChina kubva kuNational Medical Products Administration (NMPA) senzira yekurapa varwere vakuru vane epithelial yepamusoro (FIGO Stages III and IV) yepamusoro-soro...Verenga zvakawanda»

Musi wa7 Kukadzi, 2025, Sichuan Kelun-Biotech Biopharmaceutical yakazivisa kubvumidzwa kweCetuximab N01 Injection yayo neNational Medical Products Administration yekurapa kenza yemudumbu yakapararira (mCRC) muChina. Kubvumidzwa uku kwakavakirwa pakudzidza kukuru kwekiriniki kwechikamu chechitatu...Verenga zvakawanda»

Musi wa10 Kukadzi, 2025, CARsgen Therapeutics yakazivisa kuti munhu wekutanga akarapwa nekurapa kweBCMA CAR-T allogeneic kwakagadzirwa papuratifomu yeTHANK-u Plus™, akawana mhinduro yakakwana (sCR) uye negativity shoma yezvirwere zvinosara (MRD) pakuongorora kweZuva-28. Yakagadzirwa mumba...Verenga zvakawanda»

Musi wa29 Ndira, 2025, chikwata chekutsvagisa chekuChina chakaburitsa chinyorwa chine musoro unoti "Neoadjuvant pyrotinib uye trastuzumab mukenza yemazamu ine HER2 isina mhinduro yekutanga (NeoPaTHer): kushanda zvakanaka, kuchengetedzeka, uye kuongororwa kwebiomarker kwechidzidzo chinotarisirwa, chine nzvimbo dzakawanda, chakagadziriswa mhinduro" mu...Verenga zvakawanda»

Musi wa26 Ndira, 2025, Center for Drug Evaluation (CDE) yeChina National Medical Products Administration yakazivisa kuti jekiseni reLM-108 rakaitirwa kuti rivepo mukurapa kwezvirwere zvakasimba zvine microsatellite instability (MSI-H) kana mismatch repair defects (dMMR) th...Verenga zvakawanda»

Musi wa20 Ndira, National Medical Products Administration (NMPA) yakabvumidza mushonga mutsva wekudzivirira chirwere chevanhu chinonzi tagitanlimab (yaimbova KL-A167) we cisplatin ne gemcitabine wekurapa varwere vekare kana kuti vakapararira mu nasopharyngeal carcinoma (NPC). ...Verenga zvakawanda»

Musi wa16 Ndira, 2025, National Medical Products Administration (NMPA) yeChina yakabvumidza New Drug Application (NDA) ye limertinib yekurapa varwere vakuru vane EGFR T790M-mutated non-small cell lung cancer (NSCLC) yakakwira kana kuti yakapararira munharaunda. Nezve Limertinib Limertinib ...Verenga zvakawanda»

Musi wa8 Ndira, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yeChina yakapa Breakthrough Therapy Designation (BTD) yeIBI343, mushonga unonyanya kushandiswa pakurapa CLDN18.2 ADC, semushonga mumwe chete wekurapa CLDN18.2-positive advanced pancr...Verenga zvakawanda»

Musi wa8 Ndira, 2025, 9MW2821 yakapihwa Breakthrough Therapy Designation (BTD) neCenter for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) muChina. 9MW2821 inopihwa pamwe chete netoripalimab, antibody inorwisa PD-1 monoclonal, yekurapa isina mushonga, isina mushonga...Verenga zvakawanda»